Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography
Excerpt from the Press Release:
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies at the virtual Society of Cardiovascular Computed Tomography (SCCT) 16th Annual Scientific Meeting. The studies demonstrate computed tomography angiography (CTA) analysis capabilities are expanded when using Elucid’s AI software to objectively quantify intraplaque hemorrhage (IPH) and lipid-rich necrotic core (LRNC) as well as automatically determine histologically defined plaque stability phenotypes across all epicardial vessels.
Prior to utilizing Elucid’s AI software, CTA has been increasingly used in the diagnosis of vascular disease. However, in the study “Intraplaque Hemorrhage and Lipid-Rich Necrotic Core may be Objectively Quantified using Histopathologic Correlates Automatically from CTA,” delineation of IPH is reported for the first time by any software. Adding to the current clinically labelled ability to accurately delineate LRNC, the method is able to discriminate between the two effectively. Blinded to histology, CTA was analyzed using the ElucidVivo® software (previously known as vascuCAP) and provided results that agreed with histopathologic references and linearity of both tissue types independently. Results indicated that LRNC and IPH may be quantitatively measured from routinely available CTA, which increases its diagnostic power and expands the landscape of clinical decision support tools for tailored therapeutics.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?